[go: up one dir, main page]

MA41120A - Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci - Google Patents

Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Info

Publication number
MA41120A
MA41120A MA041120A MA41120A MA41120A MA 41120 A MA41120 A MA 41120A MA 041120 A MA041120 A MA 041120A MA 41120 A MA41120 A MA 41120A MA 41120 A MA41120 A MA 41120A
Authority
MA
Morocco
Prior art keywords
hepe
treating
methods
compositions including
preventing fibrosis
Prior art date
Application number
MA041120A
Other languages
English (en)
Inventor
John Climax
Kevin Duffy
Jonathan Rowe
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MA41120A publication Critical patent/MA41120A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041120A 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci MA41120A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086535P 2014-12-02 2014-12-02

Publications (1)

Publication Number Publication Date
MA41120A true MA41120A (fr) 2017-10-10

Family

ID=56092410

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041120A MA41120A (fr) 2014-12-02 2015-12-01 Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Country Status (17)

Country Link
US (1) US10363235B2 (fr)
EP (2) EP3988101A1 (fr)
JP (2) JP6986445B2 (fr)
KR (1) KR20170102879A (fr)
CN (2) CN112245419A (fr)
AU (2) AU2015358512B2 (fr)
BR (1) BR112017011685A2 (fr)
CA (1) CA2968980A1 (fr)
ES (1) ES2900593T3 (fr)
IL (2) IL252431B (fr)
MA (1) MA41120A (fr)
MX (2) MX382116B (fr)
PH (1) PH12017501022B1 (fr)
RU (2) RU2721555C2 (fr)
SG (2) SG11201704495VA (fr)
WO (1) WO2016090030A1 (fr)
ZA (2) ZA201704463B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2019110980A (ru) * 2014-01-10 2019-08-26 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
EP4218736A3 (fr) 2015-12-18 2023-10-18 Afimmune Limited Compositions à base de 15-hepe
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
WO2001049282A2 (fr) * 2000-01-06 2001-07-12 Martek Biosciences Corporation Preparations therapeutiques d'acides gras fortement insatures
AU3846801A (en) 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (fr) 2003-12-31 2005-07-14 Igennus Limited Formulation contenant un acide carboxylique ou un ester de celui-ci
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
WO2008021192A2 (fr) * 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Marqueurs de la maladie du foie gras non alcoolique (nafld) et de la stéatose non alcoolique (nash) et procédés d'utilisation
US8042070B2 (en) * 2007-10-23 2011-10-18 International Business Machines Corporation Methods and system for analysis and management of parametric yield
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009154230A1 (fr) 2008-06-17 2009-12-23 持田製薬株式会社 Agent de prévention/amélioration ou de traitement de la stéatose hépatique non alcoolique
WO2010120880A1 (fr) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Traitement de maladies hépatiques avec un inhibiteur de caspase
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2013040324A1 (fr) * 2011-09-16 2013-03-21 Galectin Therapeutics, Inc. Utilisation de compositions de galacto-rhamno-galacturonate pour traiter la stéatohépatite non alcoolique et la stéatose hépatique non alcoolique
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013082265A1 (fr) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprenant des acides gras contenant 20 atomes de carbone et leurs procédés de préparation et leur utilisation
CA2859573A1 (fr) * 2011-12-16 2013-06-20 Tarix Pharmaceuticals Ltd. Angiotensines pour le traitement d'une fibrose
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2858496B9 (fr) 2012-05-10 2023-11-29 Solutex NA LLC Huiles ayant une activité anti-inflammatoire contenant des médiateurs de prorésolution spécialisés naturels et leurs précurseurs
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
TWI689489B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EP4218736A3 (fr) 2015-12-18 2023-10-18 Afimmune Limited Compositions à base de 15-hepe

Also Published As

Publication number Publication date
EP3226873A1 (fr) 2017-10-11
IL287983A (en) 2022-01-01
IL252431B (en) 2021-12-01
EP3988101A1 (fr) 2022-04-27
ZA201704463B (en) 2018-11-28
BR112017011685A2 (pt) 2018-01-02
ZA201804380B (en) 2021-03-31
JP2017536380A (ja) 2017-12-07
SG11201704495VA (en) 2017-06-29
MX2017007000A (es) 2017-12-07
KR20170102879A (ko) 2017-09-12
AU2015358512A1 (en) 2017-07-20
IL252431A0 (en) 2017-07-31
MX2021005080A (es) 2021-06-15
MX382116B (es) 2025-03-13
PH12017501022A1 (en) 2017-11-27
WO2016090030A1 (fr) 2016-06-09
EP3226873B1 (fr) 2021-10-27
ES2900593T3 (es) 2022-03-17
HK1245101A1 (zh) 2018-08-24
RU2017122758A (ru) 2019-01-09
CA2968980A1 (fr) 2016-06-09
US10363235B2 (en) 2019-07-30
AU2021203189A1 (en) 2021-06-10
SG10202010594WA (en) 2020-12-30
PH12017501022B1 (en) 2022-02-16
RU2020115523A (ru) 2021-01-27
RU2721555C2 (ru) 2020-05-20
AU2015358512B2 (en) 2021-02-18
JP6986445B2 (ja) 2021-12-22
US20160184252A1 (en) 2016-06-30
CN112245419A (zh) 2021-01-22
CN107206008A (zh) 2017-09-26
RU2017122758A3 (fr) 2019-06-13
EP3226873A4 (fr) 2018-08-08
JP2022031813A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
EP3658612A4 (fr) Formation de particules comprenant des agents
EP3481434A4 (fr) Compositions à base de crispr/cas9 et méthodes de traitement de dégénérescences de la rétine
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA45192A (fr) Traitement d'association
EP3344274A4 (fr) Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales
ME03487B (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EP3324978A4 (fr) Compositions d'oligonucléotides et méthodes associées
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3380095A4 (fr) Compositions et méthodes de traitement d'un avc ischémique
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
MA46750A (fr) Méthodes de traitement de l'htap à l'aide de combinaisons de ralinepag et d'autres agents
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3317290A4 (fr) Compositions et méthodes de traitement d'une infection virale
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique